All In MedTech

Device Trial Radar · NCT01170234

Exhaled Nitric Oxide as a Biomarker of Disease Activity in Eosinophilic Esophagitis

Last checked: Nov 19, 2026Latest source record: Apr 16, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

14

Actual

Start

Aug 2010

Primary completion

Feb 2012

Study completion Feb 2012

Sponsor

Lead sponsor
Tufts Medical CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jul 27, 2010

More device trials from this sponsor

Design

Study type
Observational
Who can join
All sexes, from 7 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

There is currently no reliable, noninvasive biomarker for eosinophilic esophagitis (EoE), a chronic allergic diseases characterized by significant infiltration of eosinophils in the esophagus. Because eosinophils release nitric oxide, levels of exhaled nitric oxide (FeNO) are used routinely for guiding treatment in subsets of patients with asthma. FeNO levels are also elevated in immunological diseases that do not involve the airways. The investigators hypothesize that patients with EoE have elevated nitric oxide concentration in their exhaled breath and that changes in FeNO levels could be used to measure disease activity. The objective of this study is to determine the feasibility of using FeNO as a noninvasive surrogate marker for EoE disease activity. The investigators propose to measure serial exhaled nitric oxide (FeNO) levels on a group of patients with confirmed EoE, before, during and after the course of topical corticosteroid therapy to determine whether the level declines from pre-treatment level in individual patients.

Conditions

  • Eosinophilic Esophagitis

Interventions

  • NIOX MINO® Airway Inflammation MonitorDevice

    We will measure exhaled nitric oxide of patients with eosinophilic esophagitis pre-, during and post- treatment at pre-defined time intervals.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Exhaled nitric oxide as a biomarker for disease activity in eosinophilic esophagitisTime frame: 2 years
  2. Exhaled nitric oxide as a biomarker for disease activity in eosinophilic esophagitisTime frame: 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Tufts Medical Center

    Boston, Massachusetts

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.